The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

The Optimal Duration of Pertuzumab Treatment for Patients With HER2+ Breast Cancer

Gunter von Minckwitz, MD, PhD
Published Online:4:40 PM, Tue September 19, 2017

Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses questions still surrounding the optimal duration of pertuzumab (Perjeta) treatment for patients with HER2-positive breast cancer.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.